🇺🇸·3d agoIndustry
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Publisher
E
Eli Lilly News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investor.lilly.com
Leave the platform to read the original full article on the publisher site.
Source: Eli Lilly News
Scope: Industry
Related coverage
More related coverage
Ipsen·9h ago
Choosing the hardest problems: why Ipsen focuses where unmet need is greatest
Ipsen RSS·9h ago
Choosing the hardest problems: why Ipsen focuses where unmet need is greatest
Hyman, Phelps & McNamara (FDA Law)·16h ago
FDA Issues Final Guidance for Content of Human Factors Information in Medical Device Submissions
Natco Pharma·17h ago